Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Authors
Keywords
Metastatic, Colorectal cancer, Claudin-1, Antibody, Targeted therapy
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 36, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-06-28
DOI
10.1186/s13046-017-0558-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies
- (2017) M. Del Rio et al. EUROPEAN JOURNAL OF CANCER
- FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer
- (2016) L Marzi et al. BRITISH JOURNAL OF CANCER
- Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
- (2015) J. Randolph Hecht et al. CANCER TREATMENT REVIEWS
- Metastatic Colorectal Cancer: Current State and Future Directions
- (2015) Marwan G. Fakih JOURNAL OF CLINICAL ONCOLOGY
- Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody
- (2015) Laurent Mailly et al. NATURE BIOTECHNOLOGY
- Claudin-1 enhances tumor proliferation and metastasis by regulating cell anoikis in gastric cancer
- (2015) Jie Huang et al. Oncotarget
- Claudin-1 overexpression in intestinal epithelial cells enhances susceptibility to adenamatous polyposis coli-mediated colon tumorigenesis
- (2014) Jillian L Pope et al. Molecular Cancer
- Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling
- (2013) Jillian L Pope et al. GUT
- Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
- (2013) Felipe De Sousa E Melo et al. NATURE MEDICINE
- A colorectal cancer classification system that associates cellular phenotype and responses to therapy
- (2013) Anguraj Sadanandam et al. NATURE MEDICINE
- Specific Extracellular Matrix Remodeling Signature of Colon Hepatic Metastases
- (2013) Maguy Del Rio et al. PLoS One
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
- (2013) Laetitia Marisa et al. PLOS MEDICINE
- Properties of mouse and human IgG receptors and their contribution to disease models
- (2012) P. Bruhns BLOOD
- Drug-conjugated antibodies for the treatment of cancer
- (2012) John M. Lambert BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
- (2012) Christina Hackl et al. GUT
- Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation
- (2011) P Dhawan et al. ONCOGENE
- Claudin Family of Proteins and Cancer: An Overview
- (2010) Amar B. Singh et al. Journal of Oncology
- The claudins
- (2009) Madhu Lal-Nag et al. GENOME BIOLOGY
- Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas
- (2008) Virginie Granci et al. EUROPEAN JOURNAL OF CANCER
- Structure and function of claudins
- (2007) Gerd Krause et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now